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The role of a small transforming growth factor beta (TGF-b)-induced TIAF1 (TGF-b1-induced antiapoptotic factor) in the
pathogenesis of Alzheimer’s disease (AD) was investigated. TIAF1 physically interacts with mothers against DPP homolog 4
(Smad4), and blocks SMAD-dependent promoter activation when overexpressed. Accordingly, knockdown of TIAF1 by small
interfering RNA resulted in spontaneous accumulation of Smad proteins in the nucleus and activation of the promoter governed
by the SMAD complex. TGF-b1 and environmental stress (e.g., alterations in pericellular environment) may induce TIAF1 self-
aggregation in a type II TGF-b receptor-independent manner in cells, and Smad4 interrupts the aggregation. Aggregated TIAF1
induces apoptosis in a caspase-dependent manner. By ﬁlter retardation assay, TIAF1 aggregates were found in the hippocampi
of nondemented humans and AD patients. Total TIAF1-positive samples containing amyloid b (Ab) aggregates are 17 and 48%,
respectively, in the nondemented and AD groups, suggesting that TIAF1 aggregation occurs preceding formation of Ab. To test
this hypothesis, in vitro analysis showed that TGF-b-regulated TIAF1 aggregation leads to dephosphorylation of amyloid
precursor protein (APP) at Thr668, followed by degradation and generation of APP intracellular domain (AICD), Ab and amyloid
ﬁbrils. Polymerized TIAF1 physically interacts with amyloid ﬁbrils, which would favorably support plaque formation in vivo.
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Neurodegenerative diseases are frequently encountered in
the aging populations in the human societies. The neuro-
pathology of Alzheimer’s disease (AD) is characterized by
extracellular accumulation of ﬁbrillar amyloid b (Ab) peptide
and intracellular deposition of neuroﬁbrillary tangles made of
cytoskeletal protein tau.
1 These protein aggregates invoke
neuronal death and block neurogenesis and learning and
memory capabilities in AD patients.
Role of transforming growth factor beta (TGF-b) in the
pathogenesis of AD is controversial.
2–5 Type II receptor
for TGF-b (TbRII) is central to the TGF-b/mothers against
DPP homolog (Smad) signaling. Reduced levels of TbRII
are observed in human AD brains, and this correlates with
age-dependent neurodegeneration and AD-like disease in a
mouse model.
2 However, in a transgenic AD mouse model,
TGF-b1 is constitutively upregulated and neuronal apoptosis
occurs.
3 Increased levels of TGF-b in AD are associated with
perivascular deposition of extracellular matrix, which hinders
clearance of Ab and allows the development of cerebral
amyloid angiopathy.
4 Blockade of TGF-b/Smad innate
immune signaling mitigates Alzheimer-like pathology in
transgenic TbRII mouse model.
5
Here, we identiﬁed TGF-b1-induced antiapoptotic factor
(TIAF1) protein aggregation, which may cause neuronal
death. TIAF1, a 12-kDa TIAF1,
6 participates in TGF-b
signaling
7 and controls p53 activation.
8 TIAF1 is implicated
in the activation of TH2 helper T lymphocytes in chronic organ
rejection
9 and development of regulatory T cells,
10 as well as
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11 TIAF1 tends to
aggregate, and the protein aggregates are found in the
hippocampi of postmortem nondemented humans and
AD patients. Importantly, TIAF1 self-aggregation leads to
generation of Ab and amyloid ﬁbrils from amyloid precursor
protein (APP) in vitro.
Results
TIAF1 binds and blocks Smad4-dependent promoter
activation. TIAF1 is an effector of the TGF-b signaling.
6–8
By yeast two-hybrid analysis,
8,12–14 we determined that
TIAF1 physically interacted with Smad4 (Figure 1a). Stimu-
lation of COS7 ﬁbroblasts with TGF-b1 for 30min resulted in
the binding of endogenous TIAF1 with Smad4, and the
complex was accumulated in the nuclei (Figure 1b).
COS7 cells were infected with a retroviral small interfering
RNA-targeting TIAF1 (TIAF1si) or an empty retrovirus.
8 After
48h, spontaneous relocation of Smad3 and 4 in the nuclei
occurred in TIAF1-knockdown cells, but not in control cells, as
determined by immunoﬂuorescence microscopy (Figure 1c).
Similarly, COS7 cells were transfected with enhanced green
ﬂuorescence protein (EGFP)-Smad4 plasmid and simulta-
neously infected with retroviral TIAF1si or empty retrovirus.
Spontaneous accumulation of EGFP-Smad4 in the nuclei
was observed in TIAF1-knockdown cells in 48h (Figure 1d).
Also, human monocytic U937 cells and mouse L929
ﬁbroblasts were infected with retroviral TIAF1si or empty
retrovirus and cultured for 48h. Smad3 and 4 were sponta-
neously accumulated in the nuclei of TIAF1-knockdown cells
(Figures 1e and f). Approximately 70% of endogenous TIAF1
protein was knocked down (Figures 1c–f).
In comparison, COS7 cells were transfected with enhanced
cyan ﬂuorescence protein (ECFP)-TIAF1 or ECFP alone and
culturedfor24h.ThecellsweretreatedwithTGF-b1for1–8h,
and stained with indicated speciﬁc antibodies. At hour 4,
TIAF1 effectively blocked TGF-b1-mediated nuclear accumu-
lation of Smad4 (o10% nuclear localization) and Smad2/3
(35–40% nuclear localization) (Figure 1g). Similar results
were observed at hour 8. In control ECFP cells, TGF-b1-
induced nuclear accumulation of Smads was approximately
70–80% (Figure 1g).
To determine TIAF1 regulation of SMAD-governed promo-
ter activation, COS7 cells were co-transfected with ECFP-
TIAF1 and ECFP-Smad4 constructs (cyan ﬂuorescence),
along with a GFP reporter construct containing a SMAD-
responsive element or promoter.
14 Cells were then cultured
for 48h. Smad4 alone induced promoter activation
(Figure 1h). In combination, TIAF1 signiﬁcantly blocked the
promoter activation (*Po0.001, n¼3, B200 cells counted
per experiment; Student’s t test) (Figure 1h). TIAF1 or ECFP
alone had no effect on activating the SMAD-responsive
element. Both negative and positive controls were shown
(Figure 1h).
In TIAF1-knockdown cells, spontaneous activation of the
SMAD-responsive element occurred (B1.5-fold increase;
Figure 1i). Also, ectopic Smad4-regulated promoter activation
was signiﬁcantly increased in the TIAF1-knockdown cells
(B2-fold increase; Figure 1i). Altogether, TIAF1 physically
interacts with Smad4 and is likely to regulate Smad4
relocation and its transcriptional function.
TIAF1 self-binding induces apoptosis. To determine
TIAF1 in TGF-b1-regulated growth suppression, TGF-b-
sensitive mink lung Mv1Lu epithelial cells were transfected
with a mixture of ECFP and enhanced yellow ﬂuorescence
protein (EYFP) (yellow), or ECFP-TIAF1 and EYFP-TIAF1
plasmids by liposome-based GeneFector. Protein–protein
interactions were measured by FRET (Fo ¨rster/ﬂuorescence
resonance energy transfer) microscopy. TGF-b1 rapidly
induced apoptosis of cells overexpressing TIAF1/TIAF1 in
1h, but had no effect on ECFP/EYFP-expressing cells or
non-transfected cells in time-lapse microscopy (Figure 2a).
No apoptosis was observed in cells overexpressing a
dominant-negative TIAF1(E22/23A) (TIAF1 with Glu22 and
23 mutated to Ala acting as dominant negative) alone
(Figure 2a), and/or wild-type TIAF1 (Supplementary Figure
S1). Similarly, human neuroblastoma SK-N-SH cells
overexpressing TIAF1/TIAF1 were sensitive to UV light-
induced apoptosis, whereas ECFP/EYFP-overexpressing
cells were resistant (Figure 2b).
TGF-b1-induced TIAF1 self-binding occurs
independently of TbRII. In TbRII-expressing cells, TGF-b1
cross-links with TbRII for recruiting TbRI (type I receptor) and
signaling via the Smad2/3/4 complex. Human colon HCT116
cells are deﬁcient in TbRII.
14 TGF-b1 binds membrane
hyaluronidase type 2 (Hyal-2) for recruiting tumor sup-
pressor WW domain-containing oxidoreductase (WOX1)
(also named WWOX or FOR) and Smad4 to relocate to the
nuclei, which may dramatically increase the transcriptional
activation for SMAD and apoptosis.
14 HCT116 cells were
transiently overexpressed with TIAF1/TIAF1 and the cells
became sensitive to TGF-b1-induced apoptosis (Figure 2c).
We determined that when TGF-b1 increased the association
of TIAF1/TIAF1 by B100% in FRET concentration (FRETc),
cells underwent apoptosis (left panel, Figure 2c). When
cells were co-transfected with TIAF1 and Smad4,
no apoptosis was observed (right panel, Figure 2c). The
expression of Smad4 was adjusted to a low level, so as to
prevent apoptosis by ectopic Smad4.
TIAF1 self-binding induces apoptosis essentially in
every cell dependently of caspases. Transient over-
expression of TIAF1 is sufﬁcient to sensitize cells to TGF-
b1-mediated apoptosis. Human lung NCI-H1299 cells were
transfected with EYFP-TIAF1 only. TGF-b1-induced TIAF1
aggregation (see punctates) and apoptosis in cells in a
time-dependent manner (Supplementary Figure 3a and
Supplementary Video 1). EYFP alone had no effect. Similar
results were observed using other types of cells, as well as
using EGFP- or ECFP-tagged TIAF1 (data not shown).
TIAF1 self-binding is apparently a universal occurrence.
When SK-N-SH, SH-SY5Y, Mv1Lu and NCI-H1299 cells
were transiently overexpressed with TIAF1/TIAF1, apoptosis
occurred signiﬁcantly in 24h, compared with cells over-
expressing ECFP/EYFP (measured at the SubG0/G1
phase; Figure 3b). Reduction by B50–75% in the G0/G1, S
and G2/M phases of the cell cycle was shown in cells
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Cell Death and DiseaseFigure 1 TIAF1 physically binds Smad4 and blocks Smad4-regulated promoter activation. (a) By yeast two-hybrid library screening,
8,12,13 two Smad4 clones (No. 7 and
17), with an identical DNA sequence, were isolated as a TIAF1-binding protein. Both Smad4/TIAF1 interactions and positive control bindings for WOX1/p53 and MafB
self-interaction are shown, as evidenced by the growth of yeast at 371C using a selective galactose-containing agarose plate (six representative colonies). Empty pSos/pMyr
vectorsandp53/TIAF1plasmidconstructs
8,12,13wereregardedasnegativecontrols.(b)COS7cellswereculturedin10%FBSandtreatedwithorwithoutTGF-b1(5ng/ml)for
30min,followedbyisolatingcytosolicandnuclearfractionsforco-immunoprecipitationwith anti-TIAF1IgG.TGF-b1increasedthebindingof TIAF1withSmad4.Non-immune
IgG was used as a negative control in co-immunoprecipitation. (c) COS7 cells were infected with retroviral TIAF1si or empty retrovirus and cultured for 48h, followed by
determining protein nuclear localization for Smad3 and 4 by immunoﬂuorescence microscopy. TIAF1si knocked down endogenous TIAF1 protein by B70%. (d) COS7 cells
weretransfectedwith EGFP-Smad4plasmid(usingliposome)andinfectedwithretroviralTIAF1sioremptyretrovirus.Thecellsweregrownfor 48h,ﬁxedandimmunostained
with TIAF1. Nuclei were stained with DAPI. Knockdown of TIAF1 signiﬁcantly induced nuclear accumulation of EGFP-Smad4. (e and f) Human monocytic U937 cells and
mouseL929ﬁbroblastswereinfectedwithTIAF1sioremptyretrovirusandculturedfor48h,followedbyisolatingnuclearandcytosolicfractions.Spontaneousaccumulationof
Smad3 and 4 in the nuclei was shown in cells infected with TIAF1si. Reduction of endogenous TIAF1 protein by siRNA is shown (60–75% reduction; a representative set of
data from two experiments). (g) COS7 cells were transfected with ECFP or ECFP-TIAF1 expression constructs, grown for 24h, and treated with TGF-b1 (5ng/ml) for
1–8h. The extent of accumulation of Smad2, 3 or 4 in the nuclei post TGF-b1 treatment for 4h is shown (n¼3, B100 cells counted per experiment), as determined by
immunoﬂuorescence microscopy. (h) COS7 cells were transfected with a SMAD-responsive element DNA construct (using GFP as a reporter), in the presence or absence of
Smad4 and/or TIAF1 expression constructs. After 48h, positive promoter activation in cells with green ﬂuorescence was counted. Compared with Smad4 alone, TIAF1
signiﬁcantly blocked the ectopic Smad4-induced activation of the promoter (*Po0.001 for the last two bars at the right, B200 cells counted in each experiment with three
repeats; mean±S.D., Student’s t test). SP, promoter driven by SMAD. (i) COS7 cells were transfected with the SMAD promoter reporter construct and simultaneously
infected with the TIAF1si or empty retrovirus. Knockdown of TIAF1 resulted in spontaneous activation of the SMAD promoter (B1.5-fold increase). Ectopic Smad4-regulated
promoter activation was increased by B2-fold in the TIAF1-knockdown cells
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Cell Death and Diseaseoverexpressing TIAF1/TIAF1, compared with cells over-
expressing ECFP/EYFP or nothing. These observations were
reproduced in human breast cancer MCF7 and MDA-MB-231
cells, prostate DU145 cells, Jurkat T lymphocytes and murine
L929 ﬁbroblasts. TIAF1 self-binding-mediated cell death was
blocked by a pan-caspase inhibitor zVAD-FMK (30mM;
inhibition by 85%).
When TIAF1/TIAF1-expressing NCI-H1299, MCF7 and
SK-N-SH cells were exposed to TGF-b1o r- b2 for 24h,
no enhanced cell death (SubG1 phase) and growth suppression
(G0/G1phase)wereobserved(SupplementaryFiguresS2–S4).
Indeed,duringexposureofTIAF1/TIAF1-overexpressingcellsto
TGF-b1f o ro3h, there was an enhanced TIAF1 self-binding
and cell death (Figures 2 and 3b). Beyond the initial time points,
occurrence of cell death appears to depend on the extent of
TIAF1self-binding.Withoutbindinginteractionbetweenthewild-
type and mutant TIAF1, no cell death occurred (Supplementary
Figure S1).
Smad4 prevents TIAF1 self-binding and determines cell
fate. Whether Smad4 affects TIAF1 self-aggregation was
examined. NCI-H1299 cells were transiently overexpressed
with EYFP-TIAF1 and ECFP-Smad4. By time-lapse micro-
scopy, when cells expressed a greater amount of Smad4
than TIAF1 (see big blue), they were highly sensitive to
TGF-b1-induced apoptosis, as evidenced by rapid cell
shrinking and membrane blebbing (Figure 3c; see blue
line). That is, TGF-b1 activated the overexpressed Smad4 to
cause apoptosis.
15 TGF-b1 rapidly increased the binding of
TIAF1 with Smad4, followed by membrane blebbing and cell
shrinking in 8min (Figure 3c; see red line). At the death
phase, the strength of binding between Smad4 and TIAF1
reached maximally (30–50min), and the cell size reduced by
greater than 60% (Figure 3c).
When cells expressed more TIAF1 protein than Smad4,
they were refractory to TGF-b1-induced apoptosis (Figure 3d;
see green line). Although binding of TIAF1 with Smad4 was
relatively weak (see red line), no self-aggregation of TIAF1
was observed (data not shown). Similar results were
observed by testing HCT116 and L929 cells.
Figure 2 TIAF1 self-binding leads to apoptosis. (a) TGF-b-sensitive mink lung
Mv1Lu epithelial cells, overexpressing ECFP/EYFP, ECFP-TIAF1/EYFP-TIAF1 or
EYFP-TIAF1(E22/23A),wereexposedtoTGF-b1(5ng/ml).Time-lapse microscopy
was carried out (total 8h; one picture taken per 5min). TGF-b1 rapidly
induced apoptosis of TIAF1/TIAF1-expressing cells, but not ECFP/EYFP-
expressing cells, in 1h. No apoptosis was observed in cells overexpressing a
dominant-negative TIAF1(E22/23A) or in non-transfected cells. (b) Human
neuroblastoma SK-N-SH cells overexpressing TIAF1/TIAF1 were sensitive to UV
light-induced apoptosis, but ECFP/EYFP-overexpressing cells were resistant. (c)
Human TbRII-deﬁcient colon HCT116 cells, overexpressing TIAF1/TIAF1, were
treatedwithTGF-b1(5ng/ml)andimagedbytime-lapseFRETmicroscopy.TGF-b1
signiﬁcantly increased the self-binding of TIAF1/TIAF1 (left panel). When the
binding reached a maximal strength (measured as FRETc),
14 the cell underwent
apoptosis (left panel). When cells were co-transfected with TIAF1 and Smad4,
apoptosis was blocked (right panel). The expression of Smad4 was optimized to a
low level, so as to prevent apoptosis by the overexpressed Smad4 (see Figure 3)
Figure 3 Smad4 regulates TIAF1 self-binding and cell fate. (a) TGF-b1
(5ng/ml) induced self-aggregation of TIAF1 (see green punctate formation), which
leads to apoptosis of NCI-H1299 cells overexpressing EYFP-TIAF1, as determined
bytime-lapsemicroscopy.Also,seeSupplementaryVideo1.(b)Celllines,including
neuroblastoma SK-N-SH and SH-SY5Y cells, normal lung epithelial Mv1Lu cells,
and lung cancer NCI-H1299 cells, were transfected with ECFP-TIAF1 and EYFP-
TIAF1 by electroporation and then cultured for 24h. These cells underwent
apoptosis signiﬁcantly, compared with cells overexpressing ECFP and EYFP
(measured at the SubG0/G1 phase; Po0.0005, n¼3, Student’s t test). Cont,
control (no electroporation). Sham, electroporated with medium only. C/Y, ECFP
and EYFP; T/T, ECFP-TIAF1 and EYFP-TIAF1. (c) When ECFP-Smad4
was expressed at a greater level than EYFP-TIAF1 in NCI-H1299 cells, TGF-b1
(5ng/ml)rapidlyincreasedthebindingof Smad4with TIAF1in20min (red colorline
for FRETc), and concurrently cell death occurred (reduction in cell size).
(d) In contrast, cells became refractory to TGF-b1-mediated apoptosis, when the
expressed EYFP-TIAF1 level was higher than ECFP-Smad4. Under this condition,
the binding afﬁnity of these proteins was reduced
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Cell Death and DiseaseUV light rapidly induced apoptosis of NCI-H1299 cells
overexpressing TIAF1/TIAF1. Reduction in cell size by 50%
occurred at 20min, and membrane blebbing at 40min
(Supplementary Figure S5a). When cells were transfected
with ECFP-TIAF1 and EYFP-Smad4, Smad4 limited the
apoptotic response, in which membrane blebbing occurred
at 76min without reduction in cell size (Supplementary Figure
S5b). In controls, cells were overexpressed with ECFP and
EYFP only, and the kinetics showed that reduction in cell size
by 50% occurred at 120–180min, and membrane blebbing at
200–240min.
Extracellular stimuli induce TIAF1 self-polymeriza-
tion. When L929 cells were grown to 80% conﬂuence
and then exposed to TGF-b1 for 1h, TIAF1 expression was
increased (12–17kDa), along with the presence of high
molecular size proteins (43 and 46kDa; Figure 4a). Similarly,
TGF-b1 rapidly induced formation of large size TIAF1 (55 and
90kDa) in SK-N-SH cells (Figure 4a). At high cell densities
(100% and higher), multiple molecular sizes of TIAF1 are
shown in NCI-H1299 and human teratocarcinoma NT2D1 cells
(Figures 4b and c), as well as in COS7 and many other types of
cells (data not shown). These observations are in parallel with
the results from TGF-b1-induced TIAF1 self-aggregation in real
time (Figure 3a). On treatment with estrogen (E2 or 17b-
estradiol) for 24h, TIAF1 aggregation was reduced in NCI-
H1299 cells (Figure 4b). Also, UV irradiation rapidly suppressed
the aggregation in NT2D1 cells in 90min (Figure 4c).
Tumor necrosis factor (TNF)-a rapidly induced TIAF1
polymerization in L929 cells in 1h in a dose-related manner,
which correlates with generation of Ab and amyloid ﬁbrils
(Figure 4d). Monoclonal antibody against Ab (MCA2172),
which was used in the entire experiments, did not cross-react
with APP (Figure 4d, Supplementary Figures S6–S8). Also,
APP antibody (MAB348) did not bind Ab (Figure 4d, Supple-
mentary Figures S6 and S7). Amyloid ﬁbrils were stained
with Chemicon/Millipore’s (Billerica, MA, USA) antibody
against Ab oligomers. Treatment of L929 cells with TGF-b1,
-b2 and/or TNF-a for 24h resulted in induction of high
molecular sizes of TIAF1 and Ab (Supplementary Figure
S7). Failure of detection of 4.5 kDa Ab monomers was
probably because of their release from the cells to the culture
supernantants.
15 By immunoprecipitation using speciﬁc anti-
bodies against TIAF1 and Ab,A b monomer was enriched
(Figures 6d and f and 7e).
When L929 cells were grown to a high cell density, TIAF1
became a dimer (Figure 4e). Both hyaluronidase PH20
and complement C1q suppressed the expression of TIAF1
(Figure 4e). In contrast, NCI-H1299 cells expressed the
dimeric TIAF1, and C1q and PH20 promoted the formation of
TIAF1 dimer,tetramer andhighermolecular sizes(Figure4e).
TIAF1 aggregation can be superinduced, especially when
cells are cultured on the extracellular matrix derived from
other types of cells pretreated with Prima1. p53-negative
NCI-H1299 cells were cultured overnight on Petri dishes and
pretreated with or without Prima1 for 1h (to restore mutant
p53 function).
16 Thecellswere then treatedwith 50mMEDTA
(in phosphate-buffered saline) at 41C for 5min, followed by
removal using repeat pipetting. HEK293 cells were then
seeded on the matrix and grown for 24h. When cells were
grown on Prima1-activated extracellular matrix, superinduc-
tion of TIAF1 polymerization was observed (Figure 4f).
Similarly, p53-negative NCI-H1299 cells were pre-
treated with piﬁthrin m for 30min, and then exposed to
hyaluronidase PH20 for 2h. HCT116 cells were seeded onto
the extracellular matrices of NCI-H1299 cells and grown for
48h. This resulted in TIAF1 polymerization and formation
of Ab and amyloid ﬁbrils in HCT116 cells (Supplementary
Figure 4 Extracellular stimuli induce TIAF1 self-polymerization. (a) L929 and
SK-N-SH cells were grown to 80% conﬂuence and then exposed to TGF-b1 for 1h.
TIAF1 expression was increased (12–17kDa), along with the presence of high
molecular size proteins. (b and c) At high cell densities (100% and higher), high
molecular sizes of TIAF1 are shown in NCI-H1299 and human teratocarcinoma
NT2D1 cells. Estrogen (E2 or 17b-estradiol) blocked TIAF1 aggregation in
NCI-H1299cellsin24h.UVirradiationrapidlysuppressed theTIAF1aggregationin
NT2D1 cells in 90min. (d) TNF-a-induced TIAF1 polymerization in L929 cells in
1h in a dose-related manner. Generation of Ab and amyloid ﬁbrils was observed,
as determined by monoclonal antibody against Ab (MCA2172) and ﬁbril-speciﬁc
AO antibody,
36 respectively. (e) L929 and NCI-H1299 cells were grown to
100% conﬂuence (and even higher), pretreated with hyaluronidase PH20
(HAase; 200units/ml) for 30min, and then exposed to puriﬁed complement C1q
(1mg/ml) for 1h. In resting cells, TIAF1 is expressed as monomeric (17kDa) and
dimeric (35kDa) forms in L929, but as a dimeric form in NCI-H1299 (10% reducing
SDS-PAGE). Both C1q and HAase suppressed the TIAF1 expression in L929,
but promoted formation of high molecular weight forms of TIAF1 in NCI-H1299.
(f)NCI-H1299cellswereculturedovernightonPetridishesandthenpretreatedwith
or without Prima1 for 1h (to restore mutant p53 function),
16 followed by removal
of cells using EDTA and repeat pipetting. HEK293 cells were then seeded on the
matrix and grown for 24h. Superinduction of TIAF1 aggregation or polymerization
was observed, especially when cells were grown on prima1-activated extracellular
matrix. Exposure time, 15min for left panel, and 30min for right panel
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Cell Death and DiseaseFigure S8). Piﬁthrin m is an inhibitor of p53 and blocks the
binding of p53 with Bcl-xL.
17
Finally, in rat primary glial cells, TIAF1 is expressed as
17- and 24-kDa proteins and high molecular sizes at a high
cell density (Supplementary Figure S9). Lactacystin, a
proteasome inhibitor, appeared to block TIAF1 expression
(Supplementary Figure S9). Nocodazole, an inhibitor of
microtubulepolymerization, did not causeTIAF1 degradation.
Together, lactacystin and nocodazole suppressed the
expression of TIAF1 in 3h, without APP fragmentation and
Ab production (Supplementary Figure S9).
Identiﬁcation of TIAF1 aggregates in human
hippocampus. Postmortem human hippocampal tissue
sections were pre-stained with Bielschowski stain (containing
silver), followed by TIAF1 antibody
6 and ﬂuorescent IgG,
as well as Fluoro-Jade C to reveal degenerative neurons.
18
Bielschowski stain demonstrated the presence of amyloid
plaques in the human AD hippocampus (Figures 5a–c).
Degenerative neurons, positive with DAPI and Fluoro-Jade C
staining, possess TIAF1 aggregates (Figure 5a). TIAF1 aggre-
gates are shown in the extracellular matrix, without DAPI-
positive cells (Figure 5b). In negative controls, secondary
antibody only was used (Figure 5c). Confocal microscopy
analysis showed that TIAF1 aggregates may or may not
colocalize with Ab (Figure 5d; also see Supplementary Figure
S10 for serial confocal sections). TIAF1 aggregates are
normally 4100mm in diameter. Similar results were observed
when using Abcam’s (Cambridge, MA, USA) TIAF1 antibody
(data not shown). TIAF1 aggregates were found in the
interstitial tissue space in hippocampus and cortex,
suggesting that TIAF1 is secreted and becomes aggregated.
TIAF1 aggregates in APP/presenilin 1 (PS1) or APP
transgenic mice. We postulate the formation of TIAF1
aggregates preceding Ab in vivo. Expression of both proteins
was investigated in the hippocampi of 9-month-old APP/PS1
and APP only transgenic mice.
19 Many large size TIAF1
plaques (4100mm in diameter), containing small de novo
synthesized Ab in the epicenter, were observed in the
hippocampus of APP/PS1 transgenic mouse (Figure 5e,
Supplementary Figure S11). In contrast, presence of large
size Ab plaques, possessing small TIAF1 aggregates, was
also observed in the mouse hippocampus. TIAF1 debris,
rather than de novo synthesized materials, is shown (see
white arrows; Supplementary Figure S12). Residual TIAF1
aggregates are located in the epicenter of an Ab plaque
(white arrow head). TIAF1 aggregation probably occurs in
the hippocampus in the beginning followed by Ab deposition,
Figure5 TIAF1aggregatesindegenerativeneuronsintheADhippocampus.(a)Humanhippocampaltissuesectionswerepre-stainedwithBielschowskistain(containing
silver), followed by staining with speciﬁc antibody against TIAF1. Fluoro-Jade C Red was used to identify degenerative neurons. Nuclei were stained with DAPI. Sequential
magniﬁcation of aggregated TIAF1 (green; from  40 to  400) shows its colocalizationwith degenerative neurons (both in red and blue). (b) TIAF1 aggregation is shown in
the extracellular matrix containing no signal for nuclei. (c) A representative negative control. The above sections were stained with a secondary antibody(green), Fluoro-Jade
C Red and DAPI. Scale bars a–c,2 0mm for  400 magniﬁcation, and 200mm for  40 magniﬁcation. (d) A confocal image of a plaque, containing TIAF1 and Ab, is shown
( 600; also see data in Supplementary Figure S10). Scale bar, 20mm for  600 magniﬁcation. (e) A confocal image of a TIAF1 plaque, containing de novo synthesizedAb
aggregates in the epicenter, is shown from the hippocampal section of an APP/PS1 transgenic mouse (also see Supplementary Figure S11)
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Cell Death and Diseaseand that TIAF1 is likely to protect the formation of Ab
aggregates.
TIAF1 aggregates are abundant in the hippocampi of
nondemented humans. Presence of TIAF1 aggregates is
shown in water-soluble protein extracts of postmortem frozen
human hippocampi by western blots (Figure 6a). Multiple
aggregated TIAF1 forms are 4200kDa in both AD patients
and nondemented controls (Figure 6a, Supplementary
Figure S13). These aggregates are essentially devoid of
ubiquitin, as determined in western blotting using the same
blots (Supplementary Figure S13).
Filter retardation assay was carried out to determine the
presence of water-insoluble TIAF1 aggregates (40.2mmi n
diameter) in human hippocampi. TIAF1 aggregation was
present in 59.0% of postmortem nondemented human
hippocampi (age 59.0±17.0, n¼41), and 54% in older
postmortem AD patients (age 80.0±8.8, n¼97) (Figure 6c).
There were 15 and 48% for Ab aggregates in controls and
AD samples, respectively (Figure 6c). Further analysis
revealed that there was only 17% of the total TIAF1-positive
samples possessing Ab aggregates in the control group, and
48% for the AD group.
TIAF1 self-aggregation precedes production of Ab and
amyloid ﬁbrils. We validated the occurrence of TIAF1
aggregation preceding Ab in vitro. Although Ab monomer
can be secreted from cells, we enriched the monomer by
immunoprecipitation using anti-Ab antibody (AbH43) in cell
lysates (Figure 6d or see Figure 7).
Transient overexpression of TIAF1/TIAF1 in L929 cells
induced generation of amyloid ﬁbrils (AO antibody), but not
pre-ﬁbrillarAboligomers(A11antibody),asshownindotblots
(Figure 6e). Ectopic dominant-negative and wild-type TIAF1
did not generate amyloid ﬁbrils (Figure 6e). The dominant
negativedidnotbindwild-typeTIAF1,asdeterminedbyFRET
analysis. Interestingly, TGF-b1 induced the expression of pre-
ﬁbrillar Ab oligomers in ECFP/EYFP-expressing L929 cells.
Also, TIAF1/TIAF1-induced generation of APP intracellular
domain (AICD) (o10kDa) and Ab (o10kDa) (Figure 6f).
TIAF1/TIAF1 induction of amyloidﬁbril expression was shown
in Mv1Lu cells (Figure 6g) and other cells such as HCT116,
NCI-H1299, B16F10, SK-N-SH and SH-SY5Y cells (data not
shown). In supporting experiments, NCI-H1299 cells were
treated with TGF-b1, -b2, -b3, TNF-a or TNF-b for 24h, and
APP degradation occurred (Figure 6h). Exposure of B16F10
and SH-SY5Y cells to TGF-b1 for 1h showed distinct APP
degradation patterns (Figure 6i).
Figure 6 TIAF1 aggregation in vivo and generation of Ab in vitro. (a) Water-soluble TIAF1 protein aggregates were analyzed by non-reducing SDS-PAGE (5%) and
western blots using the lysates of hippocampal samples from postmortem AD patients and nondemented controls. The blots were stained with speciﬁc anti-TIAF1 antibody
(also see Supplementary Figure S13). C, control; A, Alzheimer’sdisease. (b) Filter retardation assayshows the presence of ‘water-insoluble’ TIAF1 aggregatesin control and
AD hippocampi (representative data from 138 samples). The amounts of protein loaded were 10, 30 and 60mg, respectively, from top to bottom. (c) TIAF1 aggregation is
shown in 59% of nondemented control hippocampi (age 59.0±17.0, n¼41), and only 15% of the total samples have Ab aggregates. In comparison, 54% of TIAF1
aggregationisshowninthehippocampiofolderpostmortemADpatients(80.0±8.8,n¼97),and48%ofthetotalADsamplespossessAbaggregates.Inaddition,therewas
17% of the total TIAF1-positive samples possessingAb aggregates in the control group, and 48% in the AD group. (d) L929 cells were treatedwith TNF-a (50ng/ml) for 24h.
PresenceofAbmonomer(B4.5kDa)isweaklyshowninthewholecelllysate(seeload),andthebandwasenrichedbyimmunoprecipitationusinganti-Abantibody(AbH43).
(e and f) Transiently overexpressed ECFP-TIAF1/EYFP-TIAF1 (Tc/Ty) induced generation of amyloid ﬁbrils (dot blot; AO antibody), AICD and Ab (reducing SDS-PAGE), but
not in cells overexpressing ECFP/EYFP (C/Y) or ECFP-TIAF1/mutant EYFP-TIAF1 (Tc/mTy). TGF-b1 (5ng/ml) induced the expression of preﬁbril Ab oligomers (A11
antibody)inC/Y-expressingL929cells.Mutantordominant-negativeTIAF1iswithanE22/23Aalteration.(g)SimilarexperimentswereperformedinMv1Lucells,whichshows
Tc/Ty-induced amyloid ﬁbrils (a single band under reducing SDS-PAGE; B60kDa). (h and i) NCI-H1299, B16F10 and SH-SY5Y cells were treated with medium C, TGF-b1
(5ng/ml), -b2 (5ng/ml), -b3 (5ng/ml), TNF-a (50ng/ml) and TNF-b (25ng/ml) for 24h. Distinct APP degradation patterns are shown. A representative protein gel is shown
from three repeats e–i
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Cell Death and DiseaseSK-N-SH cells were overexpressed with TIAF1/TIAF1. On
exposure to TGF-b1 for 24h, cell sizes were reduced. These
cells had signiﬁcantly overexpressed APP and Ab, compared
with control cells (Figures 7a–d). FRET analysis showed that
TGF-b1 increased the self-binding of TIAF1 during treatment
for 24h (Figures 7a–d). Importantly, phosphorylation of
endogenous APP at Thr668 was signiﬁcantly increased
in cells overexpressing TIAF1/TIAF1, and that TGF-b1
suppressed the phosphorylation (Figure 7d). Increased
phosphorylation at Thr668 in APP prevents cleavage by
g-secretase and generation of Ab40.
20
Finally, in western blotting, TGF-b1 was shown to increase
the phosphorylation of endogenous APP at Thr668, but
suppressed the binding of TIAF1 with phosphorylated APP
(B70kDa)inMCF7cells(Figure7e).TGF-b1didnotincrease
the binding of TIAF1 with Ab monomer (Figure 7e). Indeed,
TIAF1 constantly bound a basal level of Ab monomer in
COS7, L929 and other cells (data not shown). TGF-b2
increased the binding of TIAF1 with amyloid ﬁbrils in L929
cells during treatment for 24h (Figure 7f). However, exposure
of B16F10 cells to TGF-b1 for 1h reduced the binding of
TIAF1 with amyloid ﬁbrils, whereas the effect was barely
visible in HCT116 cells in this short-term experiment
(Figure 7g).
Discussion
We have discovered for the ﬁrst time that TIAF1 undergoes
self-aggregation in response to TGF-b1. TIAF1 participates in
theTGF-bsignaling.KnockdownofTIAF1withsiRNAinduces
spontaneous nuclear accumulation of Smad proteins and
activation of promoter governed by the SMAD protein
complex. TIAF1 aggregates are expressed in degenerating
neurons and form plaques in the hippocampus. Most
importantly, TIAF1 aggregates possessing Ab in the hippo-
campi are signiﬁcantly increased in postmortem AD patients
(age 71–90; n¼97), compared with younger nondemented
controls (age 42 to 76; n¼41), suggesting that formation of
TIAF1 aggregation occurs before that of Ab.
Under physiological conditions, TbRII has a central role in
the TGF-b signaling, which involves the TGF-b/Smad2/3/4
signal complex (see the schematic summary; Figure 8).
Recently, we discovered that TGF-b1 binds membrane
Hyal-2, and the TGF-b1/Hyal-2 complex recruits tumor
Figure7 TGF-b1inducesTIAF1self-association,suppressionofAPPphosphorylationatThr668,andAbsuperinduction.(aandb)SK-N-SHcells,overexpressingECFP/
EYFP or ECFP-TIAF1/EYFP-TIAF1, were treated with TGF-b1 (5ng/ml) for 24h, followed by determining the extent of protein self-binding by FRET microscopy. The
expression of APP, APP phosphorylationat Thr668 and Ab was determinedby ﬂuorescent immunostaining. (c) FRET analysiswas carriedout from 10 assays(mean±S.D.,
n¼10, Student’s t test: experiments versus non-treated C/Y controls). C/Y, ECFP/EYFP; Tc/Ty, ECFP-TIAF1/EYFP-TIAF1. (d) Comparison of protein expression proﬁles
is shown (mean±S.D., n¼50, Student’s t test: experiments versus non-treated C/Y controls). (e) TGF-b1 increased the phosphorylation of endogenous APP at Thr668
in MCF7 cells. By immunoprecipitation using speciﬁc TIAF1 antibody, TGF-b1 suppressed the binding of TIAF1 with phosphorylated APP (B70kDa), but did not affect
the binding of TIAF1 with Ab monomer. (f) TGF-b2 increased the binding of TIAF1 with amyloid ﬁbrils in L929 cells during treatment for 24h. IgH, IgG heavy chain.
(g) In comparison, exposure of B16F10 cells to TGF-b1 for 1h caused reduction in the binding of TIAF1 with amyloid ﬁbrils, whereas the effect was barely visible during this
short-term experiment for HCT116 cells. L929, B16F10 and HCT116 were grown up to 100% conﬂuence
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Cell Death and Diseasesuppressor WOX1 and Smad4 for signaling.
14 We deter-
mined here that TGF-b1 signals the binding of TIAF1 with
Smad4, and the complex relocates to the nuclei to modulate
gene transcription (Figure 8a). Smad4 is critical for supporting
the generation of membrane APP via regulation at the
gene transcription level.
21,22 Smad4 prevents TIAF1 self-
aggregation. The TGF-b/Smad4/TIAF1 signaling is expected
to occur in every normal cell. How TIAF1 affects Smad4 in
controlling APP production remains to be established.
TGF-b signaling is probably aberrant under pathological
conditions (Figure 8b).
2–5,23,24 TGF-b1 is crucial in promoting
neuroprotection and neurodegeneration.
24 Long-term over-
expression of TGF-b1 in mice causes neurodegeneration.
24
TIAF1 interacts with Thr668-phosphorylated APP, suggesting
that TIAF1 binds and stabilizes membrane APP. TGF-b1
induces TIAF1 aggregation and reduces its binding with APP,
and causes APP dephosphorylation. The dephosphorylated
APP is subjected to enzymatic cleavage and subsequent
production of Ab monomer,
20 AICD and amyloid ﬁbrils.
Aggregated TIAF1 binds amyloid ﬁbrils, which facilitates
gradual formation of TIAF1/Ab plaques. How AICD is
generated because of TIAF1 aggregation remains to be
established.
25 AICD is involved in signaling and differentiation
of neurons.
26 Thus, a balanced status of phosphorylation of
APP is critical in determining plaque formation.
Neuroblastoma, melanoma and many other cancer cells
are refractory to TGF-b-mediated growth suppression and
apoptosis.
27,28 TGF-b1 and -b2 could rapidly induce APP
degradation and production of Ab and amyloid ﬁbrils in breast
MCF7 and other cancer cells. Ab appears to be cleared up
swiftly in MCF7 cells (data not shown), suggesting a novel
mechanism for cancer cells to escape Ab cytotoxicity.
Endogenous TIAF1 is prone to aggregate under stress
stimuli, whichleadsto generationofAb andamyloidﬁbrils. UV
light, estrogen and lactacystin inhibit TIAF1 expression, or
probably induce its degradation. In vitro analyses showed that
overexpressed TIAF1 undergoes self-binding, and TGF-b1
enhances the effect. The aggregated TIAF1 appears to cause
APP phosphorylation at Thr668, which is located at the
C-terminal tail of APP presenting in the cytoplasm. By surface
plasmon-enhanced TIRF (total internal reﬂection ﬂuores-
cence) microscopy,
29,30 we have recently determined that
complement C1q destabilizes cell adherence by generating
dynamic‘turbulence’ofplasmamembraneintumorsuppressor
WOX1-expressing cells. It would be of interest to examine TGF-
b1-mediated membrane turbulence for de-phosphorylating APP
and generating Ab and amyloid ﬁbrils. Thr668-phosphorylated
APP affects the cell metabolism regarding its tendency in
generation of Ab.
26,31–33
Smad4 physically interacts with TIAF1, and the binding
prevents TIAF1 aggregation. Indeed, the concentration of
Smad4 is critical in determining the strength of its binding with
TIAF1. The overexpressed Smad4/TIAF1 complexes tend
to remain in the perinuclear area, thereby abolishing the
transcriptional function of Smad4. Overexpressed Smad4
alone induces apoptosis of cancer and neuronal cells. Smad4
is involved in the TGF-b-induced transcriptional activation of
APP gene.
21,22 Conceivably, TGF-b-induced TIAF1 aggrega-
tion and Smad4-mediated APP gene activation occur con-
currently (Figure 8), and that aggregated TIAF1 binds Smad4
to prevent nuclear relocation.
In summary, protein aggregation has a critical role in the
pathogenesis of neurodegeneration.
33–35 Apparently, TIAF1
aggregation occurs preceding generation of Ab and amyloid
Figure 8 Schematic summary of TGF-b1-induced TIAF1 self-aggregation. (a) Under physiological conditions, TGF-b1 signals via Smad2/3/4 or hyaluronidase Hyal-2.
14
Additionally,TGF-b1stimulatesthebindingofTIAF1withSmad4forrelocatingtothenucleitoregulategenetranscription.Smad4preventsTIAF1self-aggregation.(b)Altered
TGF-b signaling is expected under pathological conditions. TGF-b1 signals via TGF-b receptors or Hyal-2 for APP fragmentation and TIAF1 self-aggregation. Supporting
evidence shows that TIAF1 binds and stabilizes membrane Thr668-phosphorylated APP. TGF-b1 reduces the binding, thus leading to APP de-phosphorylation. The
dephosphorylated APP undergoes degradationand generation of Ab monomer,AICD and amyloid ﬁbrils. TIAF1 aggregates form complexeswith amyloid ﬁbrils for apoptosis
andgradualformationofTIAF1/Abplaques.Smad4mayblockTIAF1aggregation.Alternatively,TIAF1aggregatesbindcytosolicSmad4topreventnuclearaccumulationand
apoptosis. Thus, a balanced status of phosphorylation of APP is critical in determining plaque formation
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Cell Death and Diseaseﬁbrils, and the TIAF1/amyloid ﬁbril aggregates facilitate
plaque formation.
Materials and Methods
Cell lines, postmortem human hippocampi, brain tissue
sections, antibodies, immunohistochemistry, ﬂuorescence
immunostaining and confocal microscopy. Cell lines used were
human neuroblastoma SH-SY5Y and SK-N-SH cells, lung non-small cell lung
cancerNCI-H1299 cells,breast cancerMCF7and MDA-MB-231 cells, coloncancer
HCT116 cells, prostate DU145 cells, teratocarcinoma NT2D1 cells, and murine
L929 ﬁbroblasts (American Type Cell Collections). Recombinant TGF-b1 was from
PeproTech (Rocky Hill, NJ, USA). Antibodies against TIAF1 were either
homemade
6 or from Abcam. Ab antibodies were from (1) AbD/Serotec
(MCA2172; Oxford, UK), (2) Covance (6E10; Princeton, NJ, USA) and (3) Santa
Cruz Biotechnologies (H43; Santa Cruz, CA, USA). Preﬁbrillar oligomer A11
antibody
36wasfromInvitrogen(Carlsbad,CA,USA).Amyloidﬁbril-speciﬁcantibody
(AO),
36 APP antibody (MAB348) and Fluoro-Jade C Red were from Chemicon/
Millipore. Antibody against phospho-APP at Thr668 was from Cell Signaling
Technology (Danvers, MA, USA). AICD antibody (SIG-39152) was from Covance.
Ab42 and Ab40 were synthesized by AnaSpec (Fremont, CA, USA). Human
postmortem hippocampaltissues, eitherfrozen or on slides,were obtained from the
Department of Pathology, University of Colorado Health Sciences Center. Informed
consents were obtained from the family members of the deceased patients.
Hippocampal tissues of transgenic APP/PS1 and APP only mice were used in this
study in accordance with the guidelines of the National Institutes of Health, USA.
Immunohistochemistry and ﬂuorescent immunostaining of tissue sections were
performed as described.
37,38
Filter retardation assay. Filter retardation assay was performed as
described.
39 Postmortem human frozen hippocampal samples (B1mg) were
homogenized using a lysis buffer (0.5% NP-40, 0.1% Triton X-100, 0.1% SDS in
PBS). After centrifugation at 13200r.p.m. for 30min at 41C, the pellets
were harvested and added 100ml DNase I buffer (20mM Tris-HCl, pH 8.0,
15mM MgCl2, 1mg/ml DNase I), and then incubated for 1h at 371C. Protein
preparations were quantiﬁed (BCA assay kit, Pierce, Waltham, MA, USA). Each
sample, containing 10, 30 and 60mg protein, respectively, was diluted in 100ml
sample buffer (1% SDS, 8% b-mercaptoethanol in PBS),boiled for 10min at 951C,
and then ﬁltered through 0.2mm cellulose acetate membranes using a dot-blot
apparatus(Bio-dotapparatus,Bio-Rad,Hercules,CA,USA).Eachwellwaswashed
by 200ml 0.1% SDS twice. Then, the membranes were analyzed by standard
western blotting to determine the presence of Ab and TIAF1.
cDNA expression constructs and Cytotrap yeast two-hybrid
analysis. TIAF1 cDNA was tagged in-frame with EGFP, ECFP or EYFP (in
pEGFP-C1, pECFP-C1, pEYFP-C1; Clontech, Mountain View, CA, USA). These
constructs were used for cell experiments as speciﬁed. To identify TIAF1-binding
proteins, TIAF1 was used as a bait protein to screen murine L929 ﬁbroblast cDNA
libraries using CytoTrap Ras rescue-based yeast two-hybrid analysis (Stratagene,
La Jolla, CA, USA), as described.
8,12,13 Binding of Smad4 with TIAF1, along with
appropriate controls, was performed using the CytoTrap system.
Epiﬂuorescence, time-lapse, confocal microscopy, FRET and
cell cycle analysis. Epiﬂuorescence, time-lapse microscopy (Nikon Eclipse
TE2000-U; Tokyo, Japan) and confocal microscopy (Olympus (Tokyo, Japan) and
Zeiss (Hamburg, Germany)) were performed to test the effect of TGF-b1 on protein
aggregation and apoptosis. Time-lapse FRET analysis was performed for TIAF1
self-bindinganditsinteractionwithSmad4.
15,29,30TheFRETimageswerecorrected
for background ﬂuorescence from an area free of cells. The spectrally corrected
FRETc was calculated using a software program (Image-Pro Plus 6.1) by Youvan’s
equation (Image-Pro 6.1, Media Cybernetics, Bethesda, MD, USA).
15,29,30 When
indicated, cells were transfected with the TIAF1 constructs and cultured for 48h,
followed by determining the extent of apoptosis and growth suppression by cell
cycle analysis using a ﬂuorescence-activated cell sorting/ﬂow cytometry machine
(BD, Sparks, MD, USA), as described.
8,12
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